A study by Topalian et al. that considered neoadjuvant therapy with nivolumab in patients with resectable MCC, regardless of MCPyV, PD-L1 and TMB status, showed that 47% of patients treated with nivolumab and underwent surgery had a complete response, while 54% of patients had a tumor reduction of ≥30% [27]. Here, CD274 is linked to neoplasm.